NO20015751L - Nevrotrofiske faktorer i behandlingen av perifer nervedysfunksjon i bekkenområdet - Google Patents

Nevrotrofiske faktorer i behandlingen av perifer nervedysfunksjon i bekkenområdet

Info

Publication number
NO20015751L
NO20015751L NO20015751A NO20015751A NO20015751L NO 20015751 L NO20015751 L NO 20015751L NO 20015751 A NO20015751 A NO 20015751A NO 20015751 A NO20015751 A NO 20015751A NO 20015751 L NO20015751 L NO 20015751L
Authority
NO
Norway
Prior art keywords
surgery
neurotrophic factors
proteins
treatment
pelvic
Prior art date
Application number
NO20015751A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015751D0 (no
Inventor
Mart Saarma
Antti Mikael Laurikainen
Jukka Olavi Hiltunen
Matti Sakari Airaksinen
Erik Martin Klinge
Original Assignee
Licentia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Licentia Ltd filed Critical Licentia Ltd
Publication of NO20015751D0 publication Critical patent/NO20015751D0/no
Publication of NO20015751L publication Critical patent/NO20015751L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
NO20015751A 1999-05-27 2001-11-26 Nevrotrofiske faktorer i behandlingen av perifer nervedysfunksjon i bekkenområdet NO20015751L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI991197A FI991197A0 (fi) 1999-05-27 1999-05-27 Neurotrooppiset tekijät lantionalueen ääreishermoston toimintahäiriön hoitamisessa
PCT/FI2000/000476 WO2000072871A1 (en) 1999-05-27 2000-05-26 Neurotrophic factors in the treatment of peripheral nerve dysfunction of pelvic area

Publications (2)

Publication Number Publication Date
NO20015751D0 NO20015751D0 (no) 2001-11-26
NO20015751L true NO20015751L (no) 2001-12-20

Family

ID=8554739

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015751A NO20015751L (no) 1999-05-27 2001-11-26 Nevrotrofiske faktorer i behandlingen av perifer nervedysfunksjon i bekkenområdet

Country Status (14)

Country Link
EP (1) EP1181042B8 (de)
JP (1) JP2003500455A (de)
KR (1) KR20020016805A (de)
CN (1) CN1365285A (de)
AT (1) ATE378061T1 (de)
AU (1) AU776275B2 (de)
CA (1) CA2373726A1 (de)
DE (1) DE60037111T2 (de)
ES (1) ES2295027T3 (de)
FI (1) FI991197A0 (de)
IL (1) IL146346A0 (de)
NO (1) NO20015751L (de)
NZ (1) NZ515379A (de)
WO (1) WO2000072871A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1365794A2 (de) 2000-07-21 2003-12-03 Lue, Tom Vorbeugung und behandlung von störungen der sexuellen erregbarkeit
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
JP2009525319A (ja) 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
DE102011051868B4 (de) * 2011-07-15 2013-02-21 ITM Isotopen Technologien München AG Verfahren zur Herstellung trägerfreier hochreiner 177Lu-Verbindungen sowie trägerfreie 177Lu-Verbindungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2109598A1 (en) * 1991-05-21 1992-11-26 Finn Hallbook Therapeutic and diagnostic methods based on neurotrophin-4- expression
DE69732350T2 (de) * 1996-03-14 2005-12-22 Washington University Persephin und verwandte wachstumsfaktoren
WO1998002178A1 (en) * 1996-07-12 1998-01-22 Massachusetts Institute Of Technology Methods of controlling axonal growth
CA2279577A1 (en) * 1997-02-04 1998-08-06 Valentis, Inc. Treatment for urinary incontinence using gene therapy techniques
AU730430B2 (en) * 1997-02-18 2001-03-08 Genentech Inc. Neurturin receptor

Also Published As

Publication number Publication date
CA2373726A1 (en) 2000-12-07
KR20020016805A (ko) 2002-03-06
AU4761000A (en) 2000-12-18
EP1181042B1 (de) 2007-11-14
NZ515379A (en) 2004-04-30
JP2003500455A (ja) 2003-01-07
EP1181042A1 (de) 2002-02-27
CN1365285A (zh) 2002-08-21
ATE378061T1 (de) 2007-11-15
NO20015751D0 (no) 2001-11-26
IL146346A0 (en) 2002-07-25
AU776275B2 (en) 2004-09-02
DE60037111D1 (de) 2007-12-27
ES2295027T3 (es) 2008-04-16
DE60037111T2 (de) 2008-10-02
WO2000072871A1 (en) 2000-12-07
FI991197A0 (fi) 1999-05-27
EP1181042B8 (de) 2008-01-23

Similar Documents

Publication Publication Date Title
HUP9603484A2 (hu) Gyógyászati készítmények és eljárás ingerületátvitel befolyásolására
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
WO2002041837A3 (en) Treatment of mucositis
IS7770A (is) Hlutleysandi mótefni gegn GDF-8 og notkun theirra
MD970227A (ro) Dihidropirimidine şi utilizarea lor
WO2002036732A3 (en) Active variants of fgf with improved specificity
MXPA02006885A (es) Bloqueo del crecimiento axonal mediado por receptor de nogo.
WO2004019884A3 (en) Agents and methods for enhancing bone formation
TR199903154T2 (xx) Meme kanserinin tedavisi ve te�hisi i�in bile�imler ve y�ntemler
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
DE69930662D1 (de) Humane rezeptortyrosinkinase
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
NO20015751D0 (no) Nevrotrofiske faktorer i behandlingen av perifer nervedysfunksjon i bekkenområdet
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
WO2000065028A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
ATE255411T1 (de) Hyaluronsäurerezeptoren bindende stoffe und deren verwendung zur behandlung von tumoren und restenose
WO1999016406A3 (en) Therapeutic method
WO2001012127A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
DE60122781D1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
Hayase et al. A Case of Blunt Traumatic Arteriovenous Malformation of the Forearm
MD1732F1 (en) Method of prognosticating the duodenal ulcerous disease evolution
ATE380884T1 (de) Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.
UA47640U (uk) Спосіб заміщення пострезекційних дефектів, що утворилися при сегментарній резекції кісткових кіст у дітей

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application